A model for the maturation of protective antibody responses to SIV envelope proteins in experimentally immunized monkeys
- 4 February 1997
- journal article
- Published by Wiley in Journal of Medical Primatology
- Vol. 26 (1-2), 51-58
- https://doi.org/10.1111/j.1600-0684.1997.tb00319.x
Abstract
Studies using live attenuated virus vaccines in the simian immunodeficiency virus (SIV) rhesus macaque model have demonstrated broad protection against experimental challenge. Protection in these studies was found to be critically dependent on the length of time postvaccination, suggesting that protective immunity involves a necessary maturation of immune responses. The current study characterizes the evolution of protective envelope‐specific antibody responses from monkeys inoculated with the highly attenuated SIV/17E‐C1 virus vaccine. For comparison, the same antibody assays were used to characterize the properties of SIV envelope‐specific antibodies elicited by inactivated whole virus and envelope subunit vaccines that failed to provide protection from experimental virus challenge. Results of these studies identify a continuous and complex maturation of envelope‐specific antibody responses during the first six to eight months postinfection. Furthermore, the time required for maturation of SIV envelope‐specific antibodies parallels the time required for the development of protective immunity against experimental challenge with heterologous strains of SIV. While no single immune correlate of protection has been identified, we suggest that a combination of antibody parameters may serve as prognostic indicators in the development of candidate AIDS vaccines.Keywords
This publication has 35 references indexed in Scilit:
- Studies of Complement-Activating Antibodies in the SIV/Macaque Model of Acute Primary Infection and Vaccine ProtectionAIDS Research and Human Retroviruses, 1995
- Passive Immunization of Rhesus Macaques against SIV Infection and DiseaseAIDS Research and Human Retroviruses, 1995
- Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infectionVeterinary Immunology and Immunopathology, 1995
- Analysis of Envelope Glycoprotein-Specific Antibodies from SIV-Infected and gp110-Immunized Monkeys in ACC and ADCC AssaysAIDS Research and Human Retroviruses, 1995
- Measurement of antibody avidity for hepatitis C virus distinguishes primary antibody responses from passively acquired antibodyJournal of Medical Virology, 1994
- Efficacy of SIV/DeltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeysAIDS, 1991
- Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160Nature, 1990
- Maturation of immunoglobulin G avidity after rubella vaccination studied by an enzyme linked immunosorbent assay (Avidity‐ELISA) and by haemolysis typingJournal of Medical Virology, 1989
- Recent rubella virus infection indicated by a low avidity of specific IgGJournal of Clinical Immunology, 1988
- Beitrag zur kollektiven Behandlung pharmakologischer ReihenversucheNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1931